United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC

Park Avenue Securities LLC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 18.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,614 shares of the biotechnology company’s stock after purchasing an additional 407 shares during the quarter. Park Avenue Securities LLC’s holdings in United Therapeutics were worth $922,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. USA Financial Formulas acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $33,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $82,000. Values First Advisors Inc. purchased a new stake in shares of United Therapeutics during the third quarter worth approximately $90,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in shares of United Therapeutics during the third quarter worth approximately $111,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on UTHR shares. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. TD Cowen raised their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Trading Up 2.5 %

Shares of NASDAQ:UTHR opened at $367.97 on Wednesday. The stock’s 50-day moving average price is $365.91 and its two-hundred day moving average price is $355.01. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm has a market cap of $16.43 billion, a price-to-earnings ratio of 16.16, a PEG ratio of 0.92 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business posted $5.38 EPS. As a group, research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $939,625.74. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 136,848 shares of company stock worth $51,515,999 in the last three months. 11.90% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.